logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Tralokinumab for atopic dermatitis

< Back

Tralokinumab for atopic dermatitis

Drugs

Skin Disease, Burns and Wound Care

November 2019


Tralokinumab is in development for the treatment of moderate to severe atopic dermatitis (AD) uncontrolled with currently available therapies in adult patients who are candidates for systematic therapy. AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could come across with sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.
Tralokinumab is a human monoclonal antibody that binds and neutralises the effect of the protein interleukin 13 (IL-13), which plays a key role in triggering immune system responses in patients leading to AD. Tralokinumab is taken subcutaneously (SC), and trial evidence suggests it has been associated with improvements in disease symptoms. If licensed, tralokinumab will offer an additional treatment option for adults with moderate to severe AD who are candidates for systematic therapy, who may or may not use steroid cream previously.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts